Literature DB >> 28296677

RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.

Pedram Argani1, Lei Zhang, Victor E Reuter, Satish K Tickoo, Cristina R Antonescu.   

Abstract

Xp11 translocation renal cell carcinoma (RCC) are defined by chromosome translocations involving the Xp11 breakpoint which results in one of a variety of TFE3 gene fusions. TFE3 break-apart florescence in situ hybridization (FISH) assays are generally preferred to TFE3 immunohistochemistry (IHC) as a means of confirming the diagnosis in archival material, as FISH is less sensitive to the variable fixation which can result in false positive or false negative IHC. Prompted by a case report in the cytogenetics literature, we identify 3 cases of Xp11 translocation RCC characterized by a subtle chromosomal inversion involving the short arm of the X chromosome, resulting in an RBM10-TFE3 gene fusion. TFE3 rearrangement was not detected by conventional TFE3 break-apart FISH, but was suggested by strong diffuse TFE3 immunoreactivity in a clean background. We then developed novel fosmid probes to detect the RBM10-TFE3 gene fusion in archival material. These cases validate RBM10-TFE3 as a recurrent gene fusion in Xp11 translocation RCC, illustrate a source of false-negative TFE3 break-apart FISH, and highlight the complementary role of TFE3 IHC and TFE3 FISH.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28296677      PMCID: PMC5391276          DOI: 10.1097/PAS.0000000000000835

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

3.  Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum.

Authors:  Pedram Argani; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Nathan Smith; Nilda Gonzalez; Peter B Illei; Marc Ladanyi; Constance A Griffin
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

4.  TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients.

Authors:  William R Sukov; Jennelle C Hodge; Christine M Lohse; Bradley C Leibovich; R Houston Thompson; Kathryn E Pearce; Anne E Wiktor; John C Cheville
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

5.  Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Authors:  Pedram Argani; Marick Laé; Brian Hutchinson; Victor E Reuter; Margaret H Collins; John Perentesis; John E Tomaszewski; John S J Brooks; Geza Acs; Julia A Bridge; Sara O Vargas; Ian J Davis; David E Fisher; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

6.  Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.

Authors:  G Altinok; M M Kattar; A Mohamed; J Poulik; D Grignon; R Rabah
Journal:  Pediatr Dev Pathol       Date:  2005-03-08

7.  Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.

Authors:  Whitney M Green; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Jonathan I Epstein; Peter B Illei; Mohamad Allaf; Marc Ladanyi; Constance A Griffin; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-08       Impact factor: 6.394

8.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

9.  Genomic heterogeneity of translocation renal cell carcinoma.

Authors:  Gabriel G Malouf; Federico A Monzon; Jérôme Couturier; Vincent Molinié; Bernard Escudier; Philippe Camparo; Xiaoping Su; Hui Yao; Pheroze Tamboli; Dolores Lopez-Terrada; Maria Picken; Marileila Garcia; Asha S Multani; Sen Pathak; Christopher G Wood; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2013-07-01       Impact factor: 12.531

Review 10.  Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.

Authors:  Carla L Ellis; John N Eble; Andrea P Subhawong; Guido Martignoni; Minghao Zhong; Marc Ladanyi; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Mod Pathol       Date:  2013-12-06       Impact factor: 7.842

View more
  27 in total

1.  Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors.

Authors:  Albert J H Suurmeijer; Wangzhao Song; Yun-Shao Sung; Lei Zhang; David Swanson; Christopher D M Fletcher; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-04-17       Impact factor: 5.006

Review 2.  MiT family translocation renal cell carcinomas: A 15th anniversary update.

Authors:  Jatin S Gandhi; Faizan Malik; Mahul B Amin; Pedram Argani; Armita Bahrami
Journal:  Histol Histopathol       Date:  2019-09-06       Impact factor: 2.303

3.  Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Authors:  Nur P Damayanti; Justin A Budka; Heba W Z Khella; Mary W Ferris; Sheng Yu Ku; Eric Kauffman; Anthony C Wood; Khunsha Ahmed; Venkata Nithinsai Chintala; Remi Adelaiye-Ogala; May Elbanna; Ashley Orillion; Sreenivasulu Chintala; Chinghai Kao; W Marston Linehan; George M Yousef; Peter C Hollenhorst; Roberto Pili
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

4.  Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Authors:  Stephanie L Skala; Hong Xiao; Aaron M Udager; Saravana M Dhanasekaran; Sudhanshu Shukla; Yang Zhang; Carrie Landau; Lina Shao; Diane Roulston; Lisha Wang; Javed Siddiqui; Xuhong Cao; Cristina Magi-Galluzzi; Miao Zhang; Adeboye O Osunkoya; Steven C Smith; Jesse K McKenney; Bryan L Betz; Jeffrey L Myers; Arul M Chinnaiyan; Scott A Tomlins; Rohit Mehra
Journal:  Mod Pathol       Date:  2017-08-25       Impact factor: 7.842

5.  TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.

Authors:  Masaya Baba; Mitsuko Furuya; Takanobu Motoshima; Martin Lang; Shintaro Funasaki; Wenjuan Ma; Hong-Wei Sun; Hisashi Hasumi; Ying Huang; Ikuma Kato; Tsuyoshi Kadomatsu; Yorifumi Satou; Nicole Morris; Baktiar O Karim; Lilia Ileva; Joseph D Kalen; Luh Ade Wilan Krisna; Yukiko Hasumi; Aiko Sugiyama; Ryoma Kurahashi; Koshiro Nishimoto; Masafumi Oyama; Yoji Nagashima; Naoto Kuroda; Kimi Araki; Masatoshi Eto; Masahiro Yao; Tomomi Kamba; Toshio Suda; Yuichi Oike; Laura S Schmidt; W Marston Linehan
Journal:  Mol Cancer Res       Date:  2019-05-01       Impact factor: 5.852

6.  A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.

Authors:  Pedram Argani; Lei Zhang; Yun-Shao Sung; Marissa J White; Karin Miller; Mark Hopkins; Donald Small; Christine A Pratilas; David Swanson; Brendan Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-08-13       Impact factor: 5.006

7.  Genetic diversity in alveolar soft part sarcoma: A subset contain variant fusion genes, highlighting broader molecular kinship with other MiT family tumors.

Authors:  Brendan C Dickson; Catherine T-S Chung; David J Hurlbut; Paula Marrano; Mary Shago; Yun-Shao Sung; David Swanson; Lei Zhang; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-08-21       Impact factor: 5.006

8.  The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.

Authors:  Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

9.  MiT family translocation renal cell carcinoma after malignant infantile osteopetrosis in childhood: a case report.

Authors:  Jing Wang; Hongyi He; Jing Zhao; Yangyang Ma; Kai Li; Lian Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

10.  TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.

Authors:  Xiao-Ming Wang; Yuping Zhang; Rahul Mannan; Stephanie L Skala; Roshni Rangaswamy; Anya Chinnaiyan; Fengyun Su; Xuhong Cao; Sylvia Zelenka-Wang; Lisa McMurry; Hong Xiao; Daniel E Spratt; Ankur R Sangoi; Lina Shao; Bryan L Betz; Noah Brown; Satish K Tickoo; Jesse K McKenney; Pedram Argani; Sounak Gupta; Victor E Reuter; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Mod Pathol       Date:  2021-04-14       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.